BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Tisch MSRCNY to Launch Phase II Stem Cell Trial for Multiple Sclerosis (MS)
Dr. Sadiq is Leading the Trial Investigating Stem Cells for MS

Tisch MSRCNY to Launch Phase II Stem Cell Trial for Multiple Sclerosis (MS)

January 15, 2016 By Cade Hildreth (CEO) 1 Comment

Tisch MS Research Center of New York
Laboratory for the Tisch MS Research Center of New York

Dedicated to identifying the cause of multiple sclerosis (MS), the Tisch MS Research Center of New York was formally launched in 2006. However, it grew out of the MS center at the Neurological Institute of New York of the Columbia University Medical Center, a group which Dr. Saud Sadiq joined in 1992.

Discover class-defining bioproduction tools.

Since that time, Dr. Sadiq has moved his research from a small 320 square foot laboratory into a 15,030 square foot facility that is now a not-for-profit research entity and the largest independent MS center in the world.

Importantly, the research center is paired with a clinical affiliate, the International Multiple Sclerosis Management Practice (IMSMP), of which Dr. Sadiq is also director. Though this clinical affiliate, thousands of MS patients now receive cutting-edge, comprehensive MS care.

bitbio

In breaking news released January 13th, 2016, Dr. Sadiq announced that the Tisch MS Research Center of New York will be pursuing a Phase II clinical trial exploring the use of stem cells in the treatment of MS.

The announcement followed positive results from a FDA-approved Phase I stem cell trial. In this Phase I trial, MS patients received multiple spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (called MSC-NPs).

Pluristyx

In addition to demonstrating positive safety and tolerability data, this Phase I trial was the first time in history that a treatment showed reversal of established disability in MS patients. Phase I patients with MS were observed to have clinical improvements in ambulatory function, limb strength, and bladder control, among other improvements.

As stated in a recent press release by Dr. Sadiq, Chief Research Scientist at Tisch MSRCNY:

Multiple Sclerosis Stem Cell Trial“Our unprecedented Phase I results have propelled us into the next phase of research,” said Dr. Saud A. Sadiq, Chief Research Scientist at Tisch MSRCNY and the study’s principal investigator. He added, “No treatment has shown reversal of established disability in MS until now. The objective improvement experienced in bladder function, vision and walking speed in both secondary and primary progressive MS is remarkable. We now plan to establish efficacy of stem cells as a reparative therapy in Phase II.”

To learn more, view our recent interview with Dr. Saud Sadiq.

*Note: BioInformant thanks Dr. Sadiq and Pamela Levin of the Tisch MSRCNY for their assistance with this article.

iPSC-derived cardiomyocte therapy
Rate this post

Filed Under: Neural Stem Cells, Stem Cells Tagged With: cell therapy, fda, MS, multiple sclerosis, news, Tisch MSRCNY

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. Amy Cummings says

    January 29, 2016 at 3:43 pm

    This is beyond exciting!!! I feel hope, true hope…Nothing compares to this feeling! Thank you for giving that wonderful feeling back to me!!

    Reply

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.